- Home
- WPP vs LEGN Comparison
WPP vs LEGN Comparison
Compare WPP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- LEGN
- Stock Information
- Founded
- WPP 1985
- LEGN 2014
- Country
- WPP United Kingdom
- LEGN United States
- Employees
- WPP N/A
- LEGN N/A
- Industry
- WPP Advertising
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- WPP Consumer Discretionary
- LEGN Health Care
- Exchange
- WPP Nasdaq
- LEGN Nasdaq
- Market Cap
- WPP 8.4B
- LEGN 7.0B
- IPO Year
- WPP N/A
- LEGN 2020
- Fundamental
- Price
- WPP $39.76
- LEGN $27.61
- Analyst Decision
- WPP Hold
- LEGN Strong Buy
- Analyst Count
- WPP 1
- LEGN 13
- Target Price
- WPP N/A
- LEGN $75.67
- AVG Volume (30 Days)
- WPP 292.2K
- LEGN 1.5M
- Earning Date
- WPP 02-27-2025
- LEGN 05-13-2025
- Dividend Yield
- WPP 2.98%
- LEGN N/A
- EPS Growth
- WPP 389.11
- LEGN N/A
- EPS
- WPP 0.62
- LEGN N/A
- Revenue
- WPP $18,454,623,978.00
- LEGN $728,303,000.00
- Revenue This Year
- WPP N/A
- LEGN $65.96
- Revenue Next Year
- WPP $1.46
- LEGN $52.55
- P/E Ratio
- WPP $12.63
- LEGN N/A
- Revenue Growth
- WPP N/A
- LEGN 112.46
- 52 Week Low
- WPP $31.52
- LEGN $29.27
- 52 Week High
- WPP $57.37
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- WPP 58.06
- LEGN 28.84
- Support Level
- WPP $39.57
- LEGN $27.43
- Resistance Level
- WPP $40.79
- LEGN $33.30
- Average True Range (ATR)
- WPP 0.46
- LEGN 1.77
- MACD
- WPP 0.26
- LEGN -0.58
- Stochastic Oscillator
- WPP 65.20
- LEGN 2.18
About WPP WPP plc
Headquartered in the United Kingdom, WPP is one of the world's largest ad holding companies based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.